Evidence map›Paper›PMID 18411419›Full record

Trial reportBlood2008

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

Issa F Khouri, Peter McLaughlin, Rima M Saliba, Chitra Hosing, Martin Korbling, Ming S Lee, L Jeffrey Medeiros, Luis Fayad, Felipe Samaniego, Amin Alousi and 10 more

Erratum issued Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01208896 (Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma), which is not on this map. Cited by 135 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 2 pooled it
19.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01208896 phase2completednot on this mapstarted 2011, after this paper: background citation

Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma

TypeinterventionalSponsorUniversity Hospital, BordeauxRan2011 to 2017Enrolled32ConditionsLymphoma, Follicular, Stem Cell TransplantationArmsReduced_intensity conditioning
3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 2 syntheses or guidelines pooled it, 293 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  4. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013
    Trial
  13. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011
    Trial
  18. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2011
    Trial
  19. Trial
  20. Trial

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Issa F KhouriDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. ikhouri@mdanderson.org
Peter McLaughlin
Rima M Saliba
Chitra Hosing
Martin Korbling
Ming S Lee
L Jeffrey Medeiros
Luis Fayad
Felipe Samaniego
Amin Alousi
Paolo Anderlini
Daniel Couriel
Marcos de Lima
Sergio Giralt
Sattva S Neelapu
Naoto T Ueno
Barry I Samuels
Fredrick Hagemeister
Larry W Kwak
Richard E Champlin
Cellular Therapeutics (United Kingdom) · GBLymphoma Research Foundation · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

Nonmyeloablative stem cell transplantation in patients with follicular lymphoma has been designed to exploit the graft-versus-lymphoma immunity. The long-term effectiveness and toxicity of this strategy, however, is unknown. In this prospective study, we analyzed our 8-year experience. Patients received a conditioning regimen of fludarabine (30 mg/m(2) daily for 3 days), cyclophosphamide (750 mg/m(2) daily for 3 days), and rituximab (375 mg/m(2) for 1 day plus 1000 mg/m(2) for 3 days). They were then given an infusion of human leukocyte antigen-matched hematopoietic cells from related (n = 45) or unrelated donors (n = 2). Tacrolimus and methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. Forty-seven patients were included. All patients experienced complete remission, with only 2 relapses. With a median follow-up time of 60 months (range, 19-94), the estimated survival and progression-free survival rates were 85% and 83%, respectively. All 18 patients who were tested and had evidence of JH/bcl-2 fusion transcripts in the bone marrow at study entry experienced continuous molecular remission. The incidence of grade 2-IV acute GVHD was 11%. Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma.

Indexed as

Hematopoietic Stem Cell TransplantationAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsB-LymphocytesCombined Modality TherapyCyclophosphamideFemaleFollow-Up StudiesGraft vs Host DiseaseGraft vs Tumor EffectHumansLymphoma, FollicularMaleAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsCyclophosphamidefludarabineMyeloablative AgonistsRituximabVidarabine

Identifiers

PMID18411419
PMCPMC4624452
OpenAlexW2097470232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.